PharmGen Science KRX:004720KOSPI
팜젠사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days6
DART filings, 7 days0
Articles tracked6since Sep 11
In Q2 2026, PharmGen Science reported revenue of ₩47.7bn, up 4.0% year on year, and operating profit of ₩1.8bn. PharmGen Science (팜젠사이언스) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 6 articles.
PharmGen Science quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩47.7bn | +4.0% | ₩1.8bn | −₩13.6bn |
| Q1 2026 | ₩43.3bn | +1.0% | ₩1.8bn | −₩988m |
| Q4 2025 derived | ₩42.8bn | -3.2% | −₩753m | −₩118bn |
| Q3 2025 | ₩41.5bn | -0.4% | ₩1.4bn | −₩2.3bn |
| Q2 2025 | ₩45.9bn | +6.9% | ₩3.3bn | ₩3.9bn |
| Q1 2025 | ₩42.9bn | +0.9% | ₩2.0bn | −₩710m |
| Q4 2024 derived | ₩44.2bn | -5.0% | ₩1.9bn | ₩3.7bn |
| Q3 2024 | ₩41.7bn | +1.2% | ₩3.1bn | −₩3.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
PharmGen Science top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
Latest PharmGen Science news Korean headlines
-
팜젠사이언스 국내외에서 소외층 건강·문화생활 지원
1 more on this story · 1 outlets
- 팜젠사이언스, 소외계층 건강·문화생활 지원머니투데이 · Sep 14 08:12




